Okay, the user wants a detailed but concise summary of the prescribing information for Fabrazyme in English. Let me start by reading through the provided text carefully.
First, the highlights mention that the information isn't exhaustive, so I need to make sure I don't miss any key points. The main sections are Indications, Dosage, Contraindications, Warnings, Adverse Reactions, Drug Interactions, and Use in Specific Populations.
The drug is approved for Fabry disease, which is a rare genetic disorder. It reduces GL-3 deposits in the kidney and other cells. Dosage is 1 mg/kg every two weeks via IV. Patients should take antipyretics before infusion. The powder is reconstituted with sterile water to make 5 mg/mL, available in 35 mg or 5 mg vials. No contraindications listed, so that's important to note.
Warnings and Precautions: Anaphylactic and allergic reactions are possible. If they occur, stop the infusion immediately and provide emergency treatment. Infusion reactions are common, around 50-55%, and can be managed with antipyretics, antihistamines, slowing the rate, or stopping. Patients with advanced disease may have cardiac issues, so they need close monitoring. Re-administration after severe reactions requires careful consideration and medical supervision.
Adverse Reactions: The most common are infusion reactions. Other serious reactions include chills, fever, dyspnea, nausea, etc. The user should report suspected adverse reactions to Genzyme or FDA.
Drug Interactions: No studies done, so no known interactions. No in vitro metabolism studies either.
Use in Specific Populations: Pregnancy and nursing mothers have registries. Pediatric and geriatric use are mentioned, but details are in the full prescribing info. Also, responses in women are noted.
I need to make sure the summary is in English, no markdown, and starts directly with the content. Also, check for any recent changes, like the 12/2008 update on anaphylaxis. The full prescribing info has sections like Clinical Pharmacology, Nonclinical Toxicology, etc., but the highlights don't go into those details.
I should structure the summary by each main section, keeping it brief. Mention the key points without going into too much detail. Highlight the main warnings, dosage, adverse reactions, and specific populations. Also, include the reporting of adverse reactions and the note about the FDA's website for the latest info.
Wait, the user said to start directly with the content, so I need to avoid any introductory text. Just list the sections with their key points. Make sure it's concise but covers all the important parts. Check for any numbers or percentages that are crucial, like 50-55% of patients having infusion reactions. Also, the reconstitution instructions and the maximum infusion rates for different weights.
I need to ensure that the summary is accurate and doesn't add any extra information beyond what's in the source. Avoid any markdown, just plain text. Also, note that the label might not be the latest, so mention the FDA website for current info.
Let me organize the information step by step, making sure each section is covered with the necessary details. Keep sentences clear and to the point. Avoid repetition. Check for any specific terms that need to be included, like "lyophilized powder" and "sterile water for injection."
Double-check the sections: Indications, Dosage, Contraindications, Warnings, Adverse Reactions, Drug Interactions, Specific Populations. Also, the patient counseling info and the revised date.
Yes, that should cover it. Now, write it in a concise manner, ensuring all key points are included without unnecessary details.
Fabrazyme (agalsidase beta) is a lyophilized powder reconstituted with sterile water for injection to yield 5 mg/mL, available in 35 mg or 5 mg single-use vials. It is indicated for Fabry disease, reducing globotriaosylceramide (GL-3) deposition in kidney capillaries and other cell types. Dosage is 1 mg/kg every two weeks via IV infusion, with antipyretics administered prior to infusion. Initial infusion rate is ≤0.25 mg/min (15 mg/hr); rate may be adjusted based on patient tolerance, with a maximum of 1.5 hours for patients ≥30 kg.
Severe anaphylactic or allergic reactions may occur during infusion, requiring immediate discontinuation and emergency treatment. Infusion reactions (50–55% of patients) are managed with antipyretics, antihistamines, reduced infusion rates, or temporary cessation. Patients with advanced Fabry disease may have compromised cardiac function, increasing risk of severe complications. Re-administration after severe reactions requires careful risk-benefit evaluation and medical supervision.
Adverse reactions include infusion-related symptoms (chills, fever, dyspnea, nausea, etc.) and less common effects like hypotension, urticaria, or pruritus. Suspected adverse reactions should be reported to Genzyme (1-800-745-4447) or FDA (1-800-FDA-1088). No drug interactions or in vitro metabolism studies were conducted. Pregnancy and nursing registries are available.
Full prescribing information includes clinical pharmacology (mechanism of action, pharmacodynamics, pharmacokinetics), nonclinical toxicity, and specific population data (pediatric, geriatric, women). Overdose management is outlined in section 10. The label may not reflect the latest FDA-approved information; consult https://www.fda.gov/drugsatfda for updates.
